发明名称 |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
摘要 |
<p>A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-a concentration, IL-2 concentration and IFN-γconcentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.</p> |
申请公布号 |
AU2011313842(A1) |
申请公布日期 |
2013.05.30 |
申请号 |
AU20110313842 |
申请日期 |
2011.10.10 |
申请人 |
TEVA PHARMACEUTICAL INDUSTRIES LTD. |
发明人 |
KASPER, LLOYD H.;SMITH, JACQUELINE Y. |
分类号 |
C07K14/47;A61K38/00;A61K38/06;A61K38/07;A61P19/08 |
主分类号 |
C07K14/47 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|